Madrigal Pharmaceuticals (MDGL) Total Liabilities (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Total Liabilities data on file, last reported at $683.9 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $683.9 million, up 139.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $683.9 million (up 139.12% YoY), and the FY2025 annual result was $656.9 million, up 128.2% from the prior year.
• Total Liabilities climbed to $683.9 million in Q1 2026 per MDGL's latest filing, from $656.9 million in the prior quarter.
• Over five years, Total Liabilities peaked at $736.7 million in Q3 2025 and troughed at $76.9 million in Q1 2022.
• A 5-year average of $299.8 million and a median of $235.2 million in 2023 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities gained 21.97% in 2024, then jumped 148.8% in 2025.
• A 5-year view of Total Liabilities shows it stood at $165.2 million in 2022, then surged by 42.4% to $235.2 million in 2023, then gained by 22.38% to $287.9 million in 2024, then soared by 128.2% to $656.9 million in 2025, then increased by 4.11% to $683.9 million in 2026.
• Business Quant data shows MDGL's Total Liabilities at $683.9 million in Q1 2026, $656.9 million in Q4 2025, and $736.7 million in Q3 2025.